Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | HTT | P42858 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21840708 | 0.81 | ALDH1A1 (0.82) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL17799191 | 0.79 | HTT (1.00) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL18980077 | 0.78 | RAB9A (0.58) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL18496207 | 0.77 | ALDH1A1 (1.00) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL18496205 | 0.77 | HTT (0.82) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL21840694 | 0.77 | RAB9A (0.82) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL21840713 | 0.76 | ALDH1A1 (0.67) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL21840703 | 0.76 | RAB9A (0.69) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL17799236 | 0.75 | RAB9A (0.47) | POLBALDH1A1RAB9AHTTMAPT | |
| SCHEMBL21840702 | 0.74 | MAPT (0.77) | POLBALDH1A1RAB9AHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113897-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-04-16 | — | — | US | claimed |
| EP-3331878-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | Arnér, Elias, Set Jenö (SE) | 2018-06-13 | — | — | EP | claimed |
| WO-2017027357-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-02-16 | — | — | WO | claimed |
| US-11110089-B2 | Pyridazinones and their use in the treatment of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CINDA PHARMA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-20200113897-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-04-16 | — | — | US | disclosed |
| EP-3331878-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | Arnér, Elias, Set Jenö (SE) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017027357-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110089-B2 | Pyridazinones and their use in the treatment of cancer | PDXK, CCNY, PNPO | POLB 929/4885ALDH1A1 819/4885RAB9A 2697/4885 |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | TXNRD3, TXNRD1, TXNRD2 | POLB 2343/4885ALDH1A1 2694/4885RAB9A 4461/4885 |
| US-20200113897-A1 | PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER | PDXK, CCNY, PNPO | POLB 929/4885ALDH1A1 819/4885RAB9A 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.